FlexShares Core Select Bond Fund (BNDC)
Live price chart, market sentiment, and community perspectives for FlexShares Core Select Bond Fund (AMEX: BNDC).
Live price chart, market sentiment, and community perspectives for FlexShares Core Select Bond Fund (AMEX: BNDC).
On our desk, the fundamental outlook for BNDC looks increasingly unappealing given its negative historical performance and a standardized yield of 3.84% that severely lags safer government alternatives. With management fees tracking roughly 32 basis points higher than top category leaders and widening secondary market trading spreads, retail and institutional appetite remains muted outside of narrow tactical windows.
Watching the recent price action around the $21.70 level, our quantitative models highlight a persistent neutral sentiment across all horizons. A mid-channel oscillation pattern is currently in play, offering a tight risk-reward setup where a minor risk of roughly 0.3% targets a 1.1% to 1.2% upside gain. However, this is strictly a range-bound play rather than a secular buy.
When evaluating the structural efficiency of BNDC for a fixed income mandate, clinicians and risk managers must note its higher operational hurdle. The net expense ratio sits at 0.38% under a contractual waiver running through March 1, 2025, and historical drawdowns reached -17.4% during prior rate shocks. Pairing these factors with a beta of 1.02 indicates the risk setup is slightly higher than optimal for a core bond allocation.
Looking at institutional ownership and short interest telemetry, BNDC experienced a short-lived surge in short interest during June before dropping off by late July to roughly 7,112 shares (0.09% of the public float). With a days-to-cover ratio hovering between 0.6 and 1.2 days, there is zero indication of an impending squeeze or major institutional accumulation.
As a fixed income strategist reviewing the FlexShares Core Select Bond Fund, the active ETF framework fails to justify its premium over passive alternatives. The trailing multi-year metrics—including a negative five-year annualized drop of -0.33%—combined with wide trading spreads and higher fee burdens, make it a difficult product to recommend for long-term capital preservation portfolios.
Explore plasma cleansing, somatic organ swaps, and BCI.